[Inhibitory effects of co-cinobufotalin oral liquor on hepatitis B in vitro].
Co-Cinobufotalin Oral Liquor (CCOL) was studied for its ability to inhibit hepatitis B virus DNA replication, HBsAg and HBeAg expression in a HBV-transfected cell line (2.2.15 cell). The result showed that ID50 (the drug concentration that inhibits HBsAg or HBeAg secretion by 50%) was 0.08 mg/ml and 0.07 mg/ml on HBsAg and HBeAg respectively. CD50 (the drug concentration that reduces cell growth by 50%) was 2.5 mg/ml. TI (therapeutic index) was 31.3 and 35.7 respectively. The present data suggest that CCOL could exert a potent antiviral activity against HBV in vitro. Southern blot showed that CCOL inhibited HBV-DNA repication in a dose-dependent manner.
Liu
Z
Z
Beijing Ditan Hospital.
Fu
X X
XX
Zhang
N L
NL
D000998:Antiviral Agents / Q000494:pharmacology*; D002018:Bufanolides / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D004261:DNA Replication / Q000187:drug effects; D006515:Hepatitis B virus / Q000235:genetics / Q000502:physiology*; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology; D008419:Materia Medica / Q000494:pharmacology*; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000821:virology; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D002018:Bufanolides; D008419:Materia Medica; C063451:cinobufotalin